If your child has been diagnosed with sickle cell disease (SCD), or you’re trying to understand what lies ahead after a positive newborn screen, here’s what you need to know: sickle cell disease is the most common inherited blood disorder in the United States, affecting approximately 100,000 Americans — and most are diagnosed within days of birth. The journey from that initial diagnosis to effective treatment has improved dramatically over the past two decades. Children born with SCD today have a greater than 95% chance of surviving to adulthood when they receive comprehensive care.
Those survival gains also reshape long-term planning for families, since life expectancy with sickle cell disease varies by genotype and by the care a child receives over time.
This guide walks through pediatric sickle cell disease from diagnosis to treatment — covering the genetics behind the disease, what those first screening results mean, the complications parents need to watch for, and the therapies (including potential cures) now available.
What Causes Sickle Cell Disease in Children?
SCD is an autosomal recessive genetic disorder. A child must inherit two copies of the abnormal hemoglobin gene — one from each parent — to have the disease. If they inherit only one copy, they have sickle cell trait (SCT), which is generally benign.
The root problem is a single amino acid substitution: valine replaces glutamic acid at position 6 of the beta-globin chain. This produces hemoglobin S (HbS), which polymerizes when oxygen levels drop. The result? Red blood cells deform into rigid, crescent-shaped “sickles” that clog small blood vessels and break apart prematurely.
Normal red blood cells live about 120 days. Sickled cells survive only 10–20 days, creating chronic hemolytic anemia and a cascade of downstream problems.
How Is Pediatric Sickle Cell Disease Diagnosed?
In the U.S., all 50 states include SCD in their newborn screening (NBS) panel. A heel-prick blood sample is collected within 24–48 hours of birth and analyzed using high-performance liquid chromatography (HPLC) or isoelectric focusing.
A positive screen is followed by confirmatory hemoglobin electrophoresis, typically at 2–3 months of age. Results identify the specific genotype:
| Genotype | Name | Severity |
|---|---|---|
| HbSS | Sickle cell anemia | Most severe — accounts for ~65% of cases |
| HbSC | Hemoglobin SC disease | Moderate — ~25% of cases |
| HbS/β⁰-thalassemia | Sickle-beta zero thalassemia | Severe (clinically similar to HbSS) |
| HbS/β⁺-thalassemia | Sickle-beta plus thalassemia | Mild to moderate |
| HbAS | Sickle cell trait | Carrier state — not SCD |
Prenatal diagnosis is also possible through chorionic villus sampling (CVS) at 10–12 weeks or amniocentesis at 15–20 weeks for families with known carrier status.
Signs and Symptoms: What Parents See First
Most newborns with SCD appear perfectly healthy. Symptoms typically emerge around 6 months of age, when protective fetal hemoglobin (HbF) levels naturally decline and HbS takes over.
Early signs include:
- Dactylitis (hand-foot syndrome) — painful swelling of fingers and toes; often the very first symptom
- Pallor and fatigue — from baseline hemoglobin levels that typically run 6–9 g/dL (compared to normal pediatric values of 11–14 g/dL)
- Jaundice — yellowish skin and eyes from elevated bilirubin due to ongoing red cell destruction
- Fussiness and irritability — often the only pain indicator in infants and toddlers
Major Complications Every Parent Should Know
Vaso-occlusive pain crises are the hallmark of SCD and the leading cause of emergency department visits. They can last hours to days and often require IV opioids for management.
But pain crises aren’t the only concern:
- Splenic sequestration — sudden trapping of blood in the spleen, causing rapid hemoglobin drops and shock. Peak risk is ages 6 months to 3 years. Parents are taught to palpate the spleen at home.
- Stroke — occurs in 11% of children with HbSS before age 20. Transcranial Doppler (TCD) screening starting at age 2 can identify children at high risk.
- Acute chest syndrome — the leading cause of SCD-related death in children, presenting with chest pain, fever, cough, and new pulmonary infiltrate on X-ray.
- Overwhelming infection — functional asplenia develops early, leaving children vulnerable to encapsulated organisms like Streptococcus pneumoniae. This is why daily penicillin prophylaxis begins at 2 months of age.
Treatment: From Daily Prevention to Potential Cure
Baseline Preventive Care
Every child with SCD should be on:
- Penicillin V prophylaxis — 125 mg twice daily from age 2 months to 3 years, then 250 mg twice daily until at least age 5
- Folic acid supplementation — 1 mg daily to support red cell production
- Full vaccination schedule — including pneumococcal (PCV13 and PPSV23) and meningococcal vaccines
- Annual TCD screening — ages 2–16 for children with HbSS and HbS/β⁰-thalassemia
Hydroxyurea: The Cornerstone Disease-Modifying Therapy
Hydroxyurea is now recommended by the NHLBI for all children with HbSS and HbS/β⁰-thalassemia starting at 9 months of age, regardless of symptom severity. It works by boosting fetal hemoglobin (HbF) production, which interferes with HbS polymerization.
The numbers speak for themselves: hydroxyurea reduces pain crises by 44%, acute chest syndrome by 57%, hospitalization rates by 58%, and need for blood transfusions by 68% (based on the landmark BABY HUG trial). Target dose is 20–35 mg/kg/day, titrated based on blood counts.
Newer FDA-Approved Therapies
- L-glutamine (Endari) — approved for ages 5+; reduces oxidative stress in sickled cells
- Voxelotor (Oxbryta) — approved for ages 4+; inhibits HbS polymerization by increasing hemoglobin’s oxygen affinity
- Crizanlizumab (Adakveo) — approved for ages 16+; a monoclonal antibody targeting P-selectin to reduce vaso-occlusion
Curative Options
Hematopoietic stem cell transplant (HSCT) from a matched sibling donor offers a cure rate exceeding 90%, with overall survival above 95% in pediatric recipients. The catch: only about 14% of children with SCD have an HLA-matched sibling.
Gene therapy has entered the picture. In December 2023, the FDA approved two gene therapies for SCD: exagamglogene autotemcel (Casgevy), a CRISPR-based therapy, and lovotibeglogene autotemcel (Lyfgenia). Both are approved for patients aged 12 and older with recurrent vaso-occlusive crises. Early results show most patients achieving near-elimination of pain episodes.
When to Go to the Emergency Room
Parents of children with SCD should seek immediate emergency care for:
- Fever ≥ 101.3°F (38.5°C) — this is a medical emergency in SCD due to infection risk
- Sudden pallor, lethargy, or rapidly enlarging spleen
- Chest pain with difficulty breathing
- Sudden weakness, slurred speech, severe headache, or vision changes (stroke warning signs)
- Persistent erection lasting more than 4 hours (priapism)
- Pain not responding to home management within 1–2 hours
Frequently Asked Questions
Can a child with sickle cell trait develop sickle cell disease?
No. Sickle cell trait (HbAS) is a carrier state, not a disease. A child with trait has one normal and one abnormal gene. They generally live normal, healthy lives. However, two parents who both carry trait have a 25% chance with each pregnancy of having a child with SCD.
At what age should hydroxyurea be started?
Current NHLBI guidelines recommend offering hydroxyurea starting at 9 months of age for children with HbSS or HbS/β⁰-thalassemia. You don’t need to wait for symptoms. Multiple studies confirm it is safe and effective in infants and toddlers.
Is sickle cell disease curable?
Yes — stem cell transplant from a matched sibling donor can cure SCD, and the newer gene therapies (Casgevy and Lyfgenia) offer potentially curative options for patients aged 12+. However, these therapies carry significant risks, costs, and eligibility requirements, so the decision is highly individualized.
How long can a child with sickle cell disease live?
Life expectancy has improved significantly. In the 1970s, median survival was about 14 years. Today, with newborn screening, penicillin prophylaxis, hydroxyurea, and comprehensive care, over 95% of children with SCD in high-income countries survive to adulthood, and many live into their 50s, 60s, and beyond.
Can children with sickle cell disease play sports?
Most children with SCD can and should participate in physical activity. The key is adequate hydration, avoiding temperature extremes, taking rest breaks, and having a clear action plan with coaches and school staff. High-altitude activities and extreme endurance events may need modification. Always discuss specific activities with your child’s hematologist.
